Cargando…
SERPINA3-ANKRD11-HDAC3 pathway induced aromatase inhibitor resistance in breast cancer can be reversed by HDAC3 inhibition
Endocrine resistance is a major challenge for breast cancer therapy. To identify the genes pivotal for endocrine-resistance progression, we screened five datasets and found 7 commonly dysregulated genes in endocrine-resistant breast cancer cells. Here we show that downregulation of serine protease i...
Autores principales: | Zhou, Jing, Zhu, Mengdi, Wang, Qi, Deng, Yiyuan, Liu, Nianqiu, Liu, Yujie, Liu, Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326080/ https://www.ncbi.nlm.nih.gov/pubmed/37414914 http://dx.doi.org/10.1038/s42003-023-05065-w |
Ejemplares similares
-
Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma
por: Huang, Renhong, et al.
Publicado: (2018) -
HDAC7 inhibits cell proliferation via NudCD1/GGH axis in triple-negative breast cancer
por: Zhu, Mengdi, et al.
Publicado: (2022) -
Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
por: Thomas, Elizabeth A.
Publicado: (2014) -
Continuous Activity Assay for HDAC11 Enabling Reevaluation
of HDAC Inhibitors
por: Kutil, Zsófia, et al.
Publicado: (2019) -
Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
por: Seo, Jinwon, et al.
Publicado: (2014)